Slide 1: First Quarter 2008 Webcast
Exhibit 99.1 First Quarter 2008 Webcast April 24, 2008
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements contained in this presentation that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially. This presentation is being made on April 24, 2008, and Alcon does not undertak
Slide 3: Business Overview
Business Overview Cary Rayment Chairman, President & CEO 3
Slide 4: Sales Highlights
Sales Highlights 1st Qtr Q1 08 Q1 07 Growth (dollars in millions) Global Sales $ 1,536.4 $ 1,322.7 16.2% Constant Currency* 9.4% Net Earnings Reported $ 429.4 $ 346.2 24.0% Diluted EPS Reported $ 1.43 $ 1.14 25.4% • Q1 2007 included a $20.8 million after-tax impact of charges related to refractive i
Slide 5: Q1 2008 Geographic Sales and Growth
Q1 2008 Geographic Sales and Growth Q1 2008 Sales by Geography $277.4 Reported: +28.6% Emerging Constant Currency*: +17.6% Markets $672.0 18.1% Reported: +5.9% U.S. 43.7% Developed International 38.2% $587.0 Reported: +24.2% Constant Currency*: 10.4% (dollars in millions) * Constant currency sales g
Slide 6: Pharmaceutical Sales
Pharmaceutical Sales Q1 2008 Sales by Therapy 1st Qtr $700 . 3 % 7.8% +13 cy* + $650 e n Curr t Consumer stan n $210.1 $600 Co $628.4 Pharma $628.4 $550 40.9% $554.5 Surgical $697.9 $500 $450 $400 Q1 2007 Q1 2008 * Constant currency sales growth is a non-GAAP measure presented to give investors a be
Slide 7: TRAVATAN Franchise Growth
TRAVATAN® Franchise Growth PGA Market Share since TRAVATAN Z® Launch (September 2006 vs. February 2008) 5.0% 4.0% +4.6% 3.0% 2.0% Retail Share Change 1.0% 0.0% -1.0% -1.3% -2.0% -3.0% -3.5% -4.0% Xalatan Lumigan Travatan® + Travatan Z® Source: WK Health 7
Slide 8: Glaucoma growth in Japan
Glaucoma growth in Japan TRAVATANZ™ Share of Japanese Prostaglandin Market 6.0% 4.9% 5.0% Japan Launch 4.0% of TRAVATANZ™ 3.0% 2.0% 1.0% 0.0% Oct-07 Nov-07 Dec-07 Jan-08 Feb-08 Mar-08 Source: IMS 8
Slide 9: Continued DuoTrav Market Development
Continued DuoTrav™ Market Development 25% DuoTrav™ Market Share by EU, Australia, and Canada 20.3% 20% 15% 10% 5% 0% Q2 06 Q3 06 Q4 06 Q1 07 Q2 07 Q3 07 Q4 07 Source: IMS 9
Slide 10: Patanol Family Continues as Market Leader
Patanol® Family Continues as Market Leader U.S. Patanol® Family Market Share Growth 76.0 +6.0 Market Share +6.2 growth since PY 75.0 74.0 73.0 72.0 71.0 70.0 69.0 68.0 67.0 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2007 2006 2008 Source: WK Health 10
Slide 11: Patanol Share Growth in Japan
Patanol® Share Growth in Japan Japan Patanol® Unit Market Share Growth 25.0% 22.3% 20.0% 13.9% 15.0% 10.0% 5.0% 0.0% Dec-06 Mar-07 Jun-07 Sep-07 Dec-07 Mar-08 Source: IMS 11
Slide 12: Patanase Approval and U.S. Nasal Market
Patanase® Approval and U.S. Nasal Market Veramyst Flonase $63 • Approved by FDA on April 15 $50 Fluticasone • Fast onset of action vs. steroids generic Nasonex $872 $1,004 • Leverage Patanol® brand equity $2.87 bio Market Others $48 Astelin Nasacort AQ $243 $347 Rhinocort AQ $248 (dollars in million
Slide 13: Surgical Sales
Surgical Sales Q1 2008 Sales by Therapy 1st Qtr $750 . 2 % 12.0% +20 cy* + Consumer e n $210.1 $700 Curr t stan n $697.9 Pharma Co $628.4 $650 Surgical $600 $697.9 45.4% $550 $580.7 $500 Q1 2007 Q1 2008 * Constant currency sales growth is a non-GAAP measure presented to give investors a better compa
Slide 14: AcrySof IOLs Driving Growth
AcrySof® IOLs Driving Growth Global Dollar Sales by Quarter of AcrySof® IOLs 300 ® ReSTOR & Toric 53.8% Global Revenue Sales Mix Natural & IQ Market Share at YE 2007* 250 Clear 18.6% 200 (dollars in millions) 150 54.7% 100 50 26.7% 0 1Q2001 1Q2002 1Q2003 1Q2004 1Q2005 1Q2006 1Q2007 1Q2008 * Sourced
Slide 15: Advanced Technology IOL Sales Trend
Advanced Technology IOL Sales Trend $50 $47.6 $45 $40 $35 Dollars in Millions $30 $25 $20 $15 $10 $5 $- Q1 05 Q2 05 Q3 05 Q4 05 Q1 06 Q2 06 Q3 06 Q4 06 Q1 07 Q2 07 Q3 07 Q4 07 Q1 08 Toric Toric CMS ReSTOR® IOL Timeline Launch Decision Aspheric Launch 15
Slide 16: Phaco Procedures Performed by Machine
Phaco Procedures Performed by Machine 100% Percent of Procedures Performed on Machine in Average Month 79% Q1 2007 Q3 2007 Q1 2008 73% 73% % of Procedures In Q1 2008, surgeons report performing over three-quarters of phaco procedures with Alcon equipment 17% 13% 11% 14% 10% 10% 0% Alcon AMO Bausch &
Slide 17: Positive Trend in Refractive Surgical Sales
Positive Trend in Refractive Surgical Sales Refractive Sales Growth $40 +160.8% $35 $30 $31.3 $25 $20 $15 $10 $12.0 $5 $0 Q1 2007 Q1 2008 (dollars in millions) 17
Slide 18: Consumer Eye Care Sales
Consumer Eye Care Sales Q1 2008 Sales by Therapy 1st Qtr 13.7% $225 2. 1% +6.2% Consumer +1 cy* e n $210.1 Curr t stan n $200 Co $210.1 Pharma $628.4 Surgical $187.5 $697.9 $175 $150 Q1 2007 Q1 2008 * Constant currency sales growth is a non-GAAP measure presented to give investors a better compariso
Slide 19: Evolution of Alcon's CLC Products
Evolution of Alcon’s CLC Products OPTI-FREE® Branded Market Share by Product OF ® Replenish ® OF® MPS ® OF ® Express® 60% 50.4% 52.4% 50% 40% 36.2% 22.5% 35.1% 26.5% 30% 0.3% 26.9% 4.3% 20% 29.0% 29.6% 10% 19.6% 5.2% 6.1% 4.1% 0% Q1 2005 Q1 2006 Q1 2007 Q1 2008 Sales $ Growth +1.8% +32.8% +12.2% Sou
Slide 20: Financial Review
Financial Review Rick Croarkin Senior Vice President, Finance and Chief Financial Officer 20
Slide 21: Q1 Gross Profit
Q1 Gross Profit Reported 2008 includes: $1,200 • WaveLight® integration charges +16.9% • Government rebate variations • Global pricing pressures $1,100 $1,138.1 2007 includes: • $24.0 mio costs related to the $1,000 2007 refractive impairment $973.7 $900 Q1 2007 Q1 2008 % of 73.6% 74.1% Sales (dolla
Slide 22: Q1 Operating Income
Q1 Operating Income Reported 2008 includes: $600 • WaveLight® integration charges +24.1% • SG&A: – Sales force additions – Shared services center $500 $500.1 2007 includes: • $32.7 mio costs related to the $400 2007 refractive impairment $403.1 $300 Q1 2007 Q1 2008 % of 30.5% 32.6% Sales (dollars in
Slide 23: Q1 Net Earnings
Q1 Net Earnings Reported 2008 includes: $500 • Decline in non-operating +24.0% income (Global credit markets) • Improvement in effective tax rate $400 $429.4 2007 includes: $346.2 • $20.8 mio after-tax impact of $300 the 2007 refractive impairment $200 Q1 2007 Q1 2008 % of 26.2% 27.9% Sales (dollars
Slide 24: Q1 Diluted EPS
Q1 Diluted EPS Reported 2008 includes: $1.50 • Share count adjustment +25.4% • Share repurchase plan changes $1.40 $1.43 $1.30 2007 includes: • Includes ($0.07) effect from the $1.20 refractive impairment $1.14 $1.10 Q1 2007 Q1 2008 (dollars in millions) 24
Slide 25: Cash Flows Analysis
Cash Flows Analysis Cash Flows from Operations $500 $400 $398.1 $300 $342.9 $200 Q1 2007 Q1 2008 25
Slide 26: 2008 Full Year Financial Guidance Revision
2008 Full Year Financial Guidance Revision • Sales range of $6.4 to $6.5 billion • Increase due to exchange rate changes • Diluted earnings per share range of $6.39 to $6.49 • Reflects increased sales due to exchange • Investment income slightly lower than originally expected • Includes retroactive
Slide 27: Alcon
Alcon
Slide 28: Non-GAAP Constant Currency Reconciliation
Non-GAAP Constant Currency Reconciliation Constant GAAP Growth Exchange (dollars in millions) Currency Rate Rate Changes Growth Rate Global Sales 16.2% (6.8) 9.4% Pharmaceutical 13.3% (5.5) 7.8% Surgical 20.2 (8.2) 12.0 Consumer 12.1 (5.9) 6.2 United States 5.9% -- 5.9% Developed International 24.2